List of Excipients in Branded Drug CYSTOGRAFIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
BRACCO DIAGNOSTICS INC	CYSTOGRAFIN	diatrizoate meglumine	0270-0149	EDETATE DISODIUM
BRACCO DIAGNOSTICS INC	CYSTOGRAFIN DILUTE	diatrizoate meglumine	0270-1410	EDETATE DISODIUM

Cystografin Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Cystografin is an established iodinated contrast product for retrograde cystography and related lower-urinary-tract imaging. Its commercial opportunity is driven less by new chemical-entity exclusivity and more by sterile manufacturing, excipient control, packaging, supply reliability, and workflow differentiation. A competitive product would need to match iodine concentration, radiopacity, sterility, stability, catheter compatibility, and clinical handling while reducing preparation time or improving tolerability.

What is Cystografin and how is it formulated?

Cystografin contains diatrizoate salts in an aqueous injectable formulation. The product is administered intravesically rather than intravenously for radiographic visualization of the bladder and urethra.

Public labeling identifies the formulation as an ionic, water-soluble contrast medium containing diatrizoate meglumine and diatrizoate sodium. The commercial presentation is a sterile, ready-to-use solution intended for urologic imaging procedures. The relevant formulation characteristics are summarized below.

Attribute	Cystografin formulation profile
Active contrast components	Diatrizoate meglumine and diatrizoate sodium
Therapeutic class	Iodinated radiographic contrast medium
Route	Intravesical administration
Primary use	Retrograde cystography and related lower-urinary-tract imaging
Dosage form	Sterile aqueous solution
Preservative strategy	Generally consistent with single-use, sterile contrast-product practice
Primary formulation risks	Osmolality, pH, iodine stability, particulate matter, sterility, container compatibility
Primary commercial buyers	Hospitals, radiology departments, urology departments, ambulatory surgical centers
Regulatory pathway for a competitor	ANDA or 505(b)(2), depending on formulation and labeling differences

The product does not depend on a complex delivery system. Its value is concentrated in the contrast agent, sterile aqueous presentation, validated container-closure system, and established clinical workflow.

What excipients are used in Cystografin?

The core excipient platform is an aqueous vehicle with pH and metal-ion control. Public product labeling should be used as the controlling source for the current quantitative composition because commercial presentations and label versions can differ.

Water for injection

Water for injection is the principal vehicle. It must support:

• Sterility and endotoxin control
• Long-term chemical stability
• Low particulate burden
• Consistent osmolality
• Compatibility with the primary container and administration equipment

For a generic or follow-on product, water quality is not a differentiating claim by itself. The manufacturing process, however, is commercially important because sterile filtration, aseptic filling, and container-closure validation determine batch release reliability.

Diatrizoate meglumine and diatrizoate sodium

These salts provide the iodine-containing radiopaque component. The counterion balance affects:

• Ionic strength
• Osmolality
• Solution pH
• Solubility
• Local tolerability
• Compatibility with packaging materials

A formulation that changes the meglumine-to-sodium ratio may create a regulatory and clinical comparability issue even if total iodine concentration remains unchanged.

Chelating or metal-control excipients

Chelating agents such as edetate derivatives are commonly used in aqueous pharmaceutical products to bind trace metals that can accelerate degradation or discoloration. If present in the applicable Cystografin presentation, the excipient may support chemical stability but is unlikely to provide meaningful standalone patent protection.

The commercial benefit comes from process robustness rather than exclusivity. A competitor should evaluate whether a chelator is needed for the target shelf life, whether it affects compatibility with administration materials, and whether its concentration can be justified by stability data.

Buffering and pH-control agents

Citrate or related buffering components may be used to control pH. Buffer selection affects:

• Diatrizoate salt stability
• Local tissue tolerability
• Compatibility with elastomeric stoppers
• Risk of precipitation after temperature excursions
• Measured osmolality and conductivity

The best commercial strategy is usually to reproduce the reference product's clinically established pH range rather than pursue aggressive pH modification. A lower-osmolality formulation may be attractive, but a substantial change could require a 505(b)(2) strategy or additional clinical support.

What excipient strategy is best for a Cystografin competitor?

The strongest strategy is a conservative, reference-matched formulation with selective improvements in packaging and workflow.

Strategy 1: Reference-matched generic solution

A formulation that matches the reference product in active salts, iodine concentration, pH, osmolality, volume, and excipient class has the clearest regulatory path. The objective is therapeutic equivalence and manufacturing efficiency, not formulation novelty.

Key development targets include:

Development parameter	Commercial objective
Total iodine concentration	Match reference performance
Diatrizoate salt ratio	Minimize clinical and regulatory deviation
pH	Match labeled and observed reference range
Osmolality	Avoid unnecessary increase
Viscosity	Enable catheter administration
Particulate matter	Meet injectable-product standards
Sterility	Support single-use clinical handling
Container closure	Prevent iodine loss, leakage, and extractables
Shelf life	Target hospital purchasing cycles and inventory flexibility

This approach is most compatible with an ANDA if the product can meet applicable sameness and bioequivalence requirements. Because intravesical contrast does not fit conventional systemic pharmacokinetic bioequivalence well, the regulatory pathway must be assessed against FDA product-specific expectations.

Strategy 2: Ready-to-use packaging

Packaging is the clearest commercial differentiation opportunity. Hospitals may value:

• Premeasured single-use containers
• Small-volume presentations for pediatric procedures
• Larger-volume presentations for adult cystography
• Luer-compatible transfer systems
• Reduced-overfill packaging
• Tamper-evident closures
• Clear labeling of iodine concentration and volume
• Packaging that reduces waste after partial use

A unit-dose syringe could reduce preparation steps, but syringe materials, extractables, plunger compatibility, terminal sterilization feasibility, and cost would require substantial validation. A flexible polymer container may reduce breakage but introduce extractables and adsorption questions.

Strategy 3: Low-volume and pediatric presentations

Pediatric urology is a focused opportunity. A competitor could develop presentations that reduce unused product and simplify dosing by procedure volume. The product should not rely on preservatives to support multidose use unless the clinical and regulatory case is strong. Single-use preservative-free packaging is more consistent with sterile intravesical administration and hospital infection-control practice.

Strategy 4: Improved storage robustness

A formulation or container that tolerates normal hospital temperature excursions could reduce product loss. Relevant studies include:

• Accelerated and long-term stability
• Freeze-thaw exposure
• High-temperature excursions
• Light exposure
• Agitation and shipping simulation
• Container-closure integrity
• Iodine concentration over time
• Color, clarity, and particulate testing

A stability claim is commercially valuable only if it improves distribution or reduces wastage. It is unlikely to create durable exclusivity without a novel container, process, or delivery system.

What patents protect Cystografin?

Cystografin is based on an old diatrizoate contrast technology. The active ingredients and basic aqueous contrast formulation are unlikely to provide meaningful new-compound patent protection. Any historical composition, use, or manufacturing patents would generally be expected to have expired given the product's age.

The practical IP position is therefore different from that of a recently approved drug:

IP category	Likely strategic significance
Diatrizoate composition patents	Low; legacy technology
Basic aqueous formulation patents	Low; likely expired or difficult to enforce
Method-of-use patents for cystography	Low unless directed to a genuinely new clinical use
Orange Book-listed patents	Must be checked against the current FDA listing; unlikely to be the principal barrier
Container or device patents	Potentially relevant for differentiated packaging
Manufacturing-process patents	Potentially relevant if a competitor uses a distinct high-yield or low-impurity process
Trademark and trade dress	Relevant to product launch and substitution strategy
Regulatory exclusivity	Unlikely to be the main barrier for this legacy product

A freedom-to-operate review should cover diatrizoate salt manufacture, sterile filling, container systems, transfer devices, and any new low-volume presentation. Patent risk is more likely to arise from packaging or manufacturing technology than from the active ingredient.

What is the Orange Book status of Cystografin?

The FDA Orange Book is the controlling source for current patent and exclusivity listings. For a legacy contrast product, the key questions are whether the reference product has an active listed patent, whether it has current regulatory exclusivity, and whether an ANDA reference product designation remains available.

An applicant should not assume that an absence of active patents eliminates regulatory risk. Other issues include:

• Reference-product designation
• FDA product-specific guidance
• Suitability of an ANDA pathway
• Labeling differences
• Sterile manufacturing requirements
• Drug shortage or supply-chain obligations
• Product-specific bioequivalence expectations

A Paragraph IV certification would matter only if an unexpired patent were listed for the reference product. If no relevant patent remains listed, an ANDA applicant would generally face a standard patent-certification analysis rather than a Paragraph IV litigation event.

When does Cystografin lose exclusivity?

Cystografin's commercial exclusivity is principally a legacy issue. Any original patents and FDA exclusivity associated with the product are expected to have expired. The remaining commercial protection comes from brand recognition, procurement relationships, manufacturing approvals, supply reliability, and the operational cost of switching products.

The most plausible generic-entry scenarios are:

1. A standard ANDA entrant matching the reference formulation and presentation.
2. A 505(b)(2) entrant with different concentration, volume, container, or administration format.
3. A hospital-focused supplier offering contract pricing and dependable inventory.
4. A broader contrast-media company adding intravesical diatrizoate to an existing portfolio.

A generic launch would not necessarily displace the branded product immediately. Hospitals may retain the established product if it has dependable supply, familiar packaging, and a low acquisition cost. Substitution is more likely when the entrant offers comparable labeling and materially better contract economics.

What regulatory pathway is available for a Cystografin generic?

An ANDA is the preferred pathway when the proposed product can demonstrate sameness to the reference product in active ingredients, strength, dosage form, route, and labeling, subject to FDA requirements.

A 505(b)(2) application may be more suitable if the product introduces:

• A new container or delivery device
• A different volume or concentration
• A materially different excipient system
• A modified administration method
• A new pediatric presentation
• A lower-osmolality or reduced-irritancy formulation

The regulatory burden increases with formulation divergence. For an intravesical contrast medium, conventional plasma pharmacokinetic studies may not be the central evidence package. FDA may focus on pharmaceutical equivalence, in vitro performance, quality attributes, clinical labeling, and justification of local exposure and tolerability.

Manufacturing controls are critical. The product is a sterile drug, and the application must address:

• Aseptic processing or terminal sterilization, if feasible
• Sterility assurance
• Bacterial endotoxins
• Particulate matter
• Extractables and leachables
• Container-closure integrity
• Hold times and bulk solution stability
• Cleaning validation
• Iodine assay and degradation products

What commercial opportunities exist for Cystografin?

Hospital contract substitution

The largest opportunity is a lower-cost, supply-secure generic. Contrast products are purchased through hospital systems, group purchasing organizations, distributors, and radiology supply contracts. A competitor needs reliable fill rates and a presentation that fits current procedure sets.

Specialty urology distribution

A focused supplier could target urology practices, pediatric hospitals, ambulatory surgical centers, and imaging centers. Smaller accounts may value convenience packaging more than the lowest unit price.

Procedure-specific packaging

Product configurations could be designed around typical cystography workflows:

Segment	Product opportunity
Pediatric urology	Small-volume, single-use containers
Adult retrograde cystography	Standard-volume ready-to-use bottles or bags
Ambulatory centers	Compact packaging with simple storage
Hospital radiology	Case-pack formats and barcode integration
Emergency procedures	Rapid-access, unit-dose packaging
Home or outpatient preparation	Only if consistent with clinical and regulatory requirements

Supply resilience

The active ingredient is an older contrast compound, but sterile production capacity, raw-material qualification, and packaging availability can still create supply constraints. A supplier with dual-source raw materials, redundant filling capacity, and domestic inventory may win contracts even without a novel formulation.

International markets

Geographic expansion depends on national registration requirements, local pharmacopoeial standards, and the availability of an approved intravesical indication. Markets with established use of diatrizoate-based cystography may be easier to enter than markets that have shifted toward other imaging modalities.

A global strategy should separate:

• United States ANDA or 505(b)(2) requirements
• European Union national or decentralized procedures
• Canadian drug-licensing requirements
• Latin American registration and import rules
• Asian sterile-product and contrast-agent requirements

Patent barriers are unlikely to be the central international issue. Local registration, pricing, distribution, and manufacturing compliance are more important.

How strong is the Cystografin patent estate?

The patent estate is likely weak as a barrier to a conventional generic. The strongest defensible positions would involve new commercial features rather than the legacy active ingredient.

Potentially protectable subject matter includes:

• A specific low-extractables container system
• A prefilled administration device
• A validated packaging configuration that reduces iodine loss
• A new sterile filling process
• A long-shelf-life formulation with a defined excipient ratio
• A procedure-specific kit combining contrast and compatible administration components

These claims would face obviousness and enablement scrutiny. A patent strategy should therefore be paired with regulatory and commercial advantages. A narrow formulation patent without meaningful purchasing or workflow benefit may have limited value.

Which companies are challenging Cystografin?

Public commercial competition is more likely to come from suppliers of generic diatrizoate products and alternative iodinated contrast media than from a visible Paragraph IV campaign. Competitive products may include other diatrizoate formulations, generic urinary-tract contrast products, and nonionic iodinated agents used off-label or under different procedural protocols.

The relevant competitor groups are:

• Generic injectable and contrast-media manufacturers
• Multinational radiology suppliers
• Contract sterile-fill manufacturers
• Hospital-brand or private-label suppliers
• Companies with urology procedure kits

The absence of prominent litigation would be consistent with an old product whose principal barriers are regulatory execution and sterile manufacturing rather than active patent enforcement.

What litigation and settlement risks affect Cystografin?

Patent litigation risk appears secondary to regulatory and commercial risk. A Paragraph IV case would depend on a currently listed, unexpired patent. Settlement agreements would be relevant only if a new patent or proprietary container system created a meaningful entry dispute.

More material risks include:

• FDA inspection findings
• Sterility failures
• Product recalls
• Container-closure defects
• Iodine assay drift
• Particulate contamination
• Supply interruption
• Contract disputes with distributors or group purchasing organizations

A competitor should treat quality-system performance as a core market-access issue. In sterile contrast products, one manufacturing event can damage hospital confidence and erase the benefit of lower pricing.

How does Cystografin compare with alternative contrast products?

Cystografin's principal advantage is its established role in intravesical cystography. Its limitations are associated with the legacy ionic formulation and the narrower procedure market.

Factor	Cystografin-type diatrizoate product	Nonionic iodinated alternative
Clinical familiarity in cystography	High in established sites	Variable
Ionicity	Ionic	Generally nonionic
Osmolality	May be higher	Often lower at comparable iodine levels
Formulation complexity	Low to moderate	Moderate
Generic development	Potentially straightforward	Product-specific
Acquisition cost	Likely favorable for generic versions	May be higher
Differentiation opportunity	Packaging, supply, workflow	Tolerability, imaging, broader use
Patent barrier	Likely low	Depends on product age and formulation

A nonionic alternative could compete on local tolerability or broader procedural adoption, but it would need a clear clinical and economic rationale. A diatrizoate generic has the simpler commercial thesis: match the reference product and reduce acquisition cost.

Key Takeaways

• Cystografin is an established intravesical iodinated contrast product based on diatrizoate salts.
• The strongest generic strategy is a reference-matched sterile aqueous formulation.
• Excipients primarily support pH control, metal-ion management, stability, and container compatibility.
• Novel excipient chemistry is less attractive than improved packaging, unit-dose presentation, and supply reliability.
• Patent barriers are likely limited because the active ingredient and core formulation technology are old.
• Orange Book status and current FDA product-specific requirements must control any ANDA or Paragraph IV analysis.
• The main competitive risks are sterile manufacturing, regulatory equivalence, container performance, and hospital procurement.
• Pediatric volumes, prefilled systems, and procedure-specific packaging offer the clearest commercial differentiation.
• Biosimilar risk is not relevant because Cystografin is a small-molecule contrast product, not a biologic.
• A successful entrant would compete through price, availability, workflow convenience, and quality consistency.

FAQs about Cystografin formulation and market entry

Is Cystografin a biologic or small-molecule drug?

Cystografin is a small-molecule iodinated contrast product. Biosimilar regulation does not apply.

Can a company launch a generic Cystografin without developing a new formulation?

Yes. The lowest-risk strategy is a formulation that matches the reference product in active ingredients, strength, dosage form, route, excipient function, and labeling, subject to FDA requirements.

Are preservatives commercially attractive in a Cystografin replacement?

Usually not. A sterile, single-use, preservative-free presentation is more consistent with intravesical procedural use and hospital infection-control practices.

Could a prefilled Cystografin syringe receive patent protection?

Potentially, if the syringe, formulation, material compatibility, or administration system provides a novel and nonobvious technical solution. Patentability would not guarantee commercial adoption.

Is a lower-osmolality Cystografin formulation an attractive opportunity?

It could be commercially attractive if it improves local tolerability without impairing imaging, stability, sterility, or catheter administration. The regulatory pathway would likely be more complex than for a reference-matched generic.

References

1. Bracco Diagnostics Inc. (n.d.). Cystografin and Cystografin Dilute prescribing information. U.S. Food and Drug Administration labeling database.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugsatfda

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. https://www.fda.gov/drugs

4. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Part 211. https://www.ecfr.gov

5. United States Pharmacopeia. (2024). General chapter <797>: Pharmaceutical compounding - sterile preparations. United States Pharmacopeial Convention.

6. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm